Please login to the form below

Not currently logged in
Email:
Password:

Eczema creams under threat

US authorities have ruled two eczema creams should carry warnings that they may increase the risk of cancer.

US authorities have ruled two eczema creams should carry warnings that they may increase the risk of cancer. The Food and Drug Administration said research had shown that Elidel and Protopic may pose a cancer risk when absorbed into the body. It said babies should not be treated with the creams at all.

The view is strongly disputed by the manufacturers, Novartis, which makes Elidel, and Fujisawa Pharmaceutical, which makes Protopic.

In a statement, the FDA said animal studies had shown a potential link with cancer. There were also reports of seven cases of lymphoma and six of skin cancer among children and adults treated with Elidel or Protopic.

Both creams work by suppressing the immune system. Depressing immune activity in this way is known to potentially contribute to cancer.

A spokesperson for the UK's Medicines and Healthcare products Regulatory Agency said it was closely monitoring the safety of the creams.

"Any patient or parent of a patient who has concerns about their treatment or their child's treatment should speak to their doctor."

Margaret Cox, chief executive of the UK's National Eczema Society, told the BBC News website that the creams already came with strong warnings about their over-use in this country.

"Because they are new treatments one does have to recognise that the long-term effects are uncertain," she said.

"To date we haven't had any evidence of direct causality between topical application of these creams in humans and cancer."

Novartis dismissed claims Elidel could increase the risk of cancer, and said it planned no immediate change in its product label.

In a statement it said: "Novartis agrees that patients suffering from mild to moderate eczema need to be informed about the safe and effective use of Elidel, but we believe a recommendation to add a black box warning to the label is unsubstantiated by clinical evidence and experience in more than five million patients worldwide."

Fujisawa Pharmaceutical said it had not found any data to clearly link Protopic to cancer, and believes it has provided sufficient information to ensure the drug is used safely.

In February, members of an FDA advisory panel said they were concerned the companies were aggressively advertising the medicines to treat infants and others with skin problems that the creams are not approved to treat.

2nd September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics